drugset / Trial / NCT02334501

Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects

NCT02334501

Phase 1 Completed 15 enrolled Puma Biotechnology, Inc.
NaSingle-groupOpen-label

Summary

This is an open label, 2-period, fixed-sequence study in 15 healthy adult subjects under fed conditions. To evaluate the effect of multiple doses of lansoprazole on the absorption and pharmacokinetics (PK) of a single dose of neratinib in healthy subjects.

Timeline

Start
2014-08
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Lansoprazole Other / unclassified 30 mg Oral
Subject Neratinib Small molecule 240 mg Oral

Indications

No indication recorded.